TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31925600

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 30957391

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin dual treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 29871668

Group type: EXPERIMENTAL
Intervention: Frequent, rapid, on-site testing and treatment (TnT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no TnT)
Number of subjects: 480
Study: 26740254

Group type: EXPERIMENTAL
Intervention: High-dose black raspberry (2500 mg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-dose black raspberry (1500 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24699059

Group type: EXPERIMENTAL
Intervention: Intravenous tissue‐type plasminogen activator followed by endovascular treatment
Number of subjects: 656

Group type: COMPARATOR
Intervention: Intravenous tissue‐type plasminogen activator alone
Number of subjects: 656
Study: 22694864

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Presence care (Control)
Number of subjects: 20
Study: 19086054

Group type: EXPERIMENTAL
Intervention: Creative-bonding intervention (CBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Friendly visit (FV) control group
Number of subjects: 100
Study: 17185020

Group type: EXPERIMENTAL
Intervention: Idursulfase at 0.15 mg/kg infused every other week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Idursulfase at 0.5 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Idursulfase at 1.5 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Idursulfase (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14660493

Group type: EXPERIMENTAL
Intervention: Deep breath (DB) intervention during methacholine-induced obstruction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deep breath (DB) intervention
Number of subjects: 18
Study: 11209583

Group type: EXPERIMENTAL
Intervention: Videotape with embedded commercials
Number of subjects: 46

Group type: COMPARATOR
Intervention: Videotape without commercials
Number of subjects: 46
Study: 9846248

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 8122594

Group type: EXPERIMENTAL
Intervention: 30 mg of dipyridamole intravenously over 1 hour, starting immediately before the procedure (group 1)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Dipyridamole administered before the procedure (group 2)
Number of subjects: 977

Group type: COMPARATOR
Intervention: No dipyridamole administered (group 3)
Number of subjects: 977
Study: 2700432

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 983794

Group type: EXPERIMENTAL
Intervention: 1 g niceritrol given three times daily (1 g X 3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 g niceritrol given twice daily (1.5 g X 2)
Number of subjects: 18
Study: 30372680

Group type: EXPERIMENTAL
Intervention: 24-month home-based physical activity program targeting 150 minutes/week of moderate physical activity
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group continued with their usual lifestyle
Number of subjects: 106
Study: 28199805

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 150

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 150
Study: 25698766

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study: 22822936

Group type: EXPERIMENTAL
Intervention: Verbal reminders
Number of subjects: 0
Study: 21512825

Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes (GA versus GG)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes (GA/AA versus GG)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among those aged ≥ 45 years
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among male subjects
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: H2AFX rs643788 A variant genotypes among patients with glioblastoma
Number of subjects: 1307
Study: 19487274

Group type: EXPERIMENTAL
Intervention: Ultrasonographic (US) scoring system of salivary glands (0-48 scale)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Scintigraphy (0-12 scale)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Salivary gland biopsy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ultrasonographic (US) scoring system
Number of subjects: 135
Study: 17156174

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (30 mg or 60 mg tablets)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Methadone mixture (1 mg/ml)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 235

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 235
Study: 14701900

Group type: EXPERIMENTAL
Intervention: Cuff on bare arm
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cuff over the sleeve
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cuff below the rolled-up sleeve
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cuff on bare arm in hypertensive subjects
Number of subjects: 201
Study: 10699069

Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy alone (n = 348)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Chemotherapy with postoperative radiotherapy (n = 346)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: 5-FU plus LV chemotherapy in male patients (n = 200)
Number of subjects: 694

Group type: COMPARATOR
Intervention: MOF chemotherapy in male patients (n = 207)
Number of subjects: 694
Study: 9116271

Group type: EXPERIMENTAL
Intervention: Centroblastic lymphoma
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: B-immunoblastic lymphoma
Number of subjects: 219

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 219

Group type: COMPARATOR
Intervention: Relapse-free survival
Number of subjects: 219
Study: 8104017

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Triprolidine 10 mg
Number of subjects: 15
Study: 3725965

Group type: EXPERIMENTAL
Intervention: Dexon (polyglycolic acid)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prolene (polypropylene)
Number of subjects: 21
Study: 30215735

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 8
Study: 30053896

Group type: EXPERIMENTAL
Intervention: PF-06438179/GP1111 (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Infliximab-EU (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Both treatments (PF-06438179/GP1111 and infliximab-EU)
Number of subjects: 650
Study: 26843085

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 12 months
Number of subjects: 80
Study: 24451619

Group type: EXPERIMENTAL
Intervention: Thermoneutral conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hot conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole‐ or lower‐body exercise (unloaded or loaded)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Upper‐body work
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mild hyperthermia
Number of subjects: 15
Study: 22429187

Group type: EXPERIMENTAL
Intervention: 12% hempseed oil (HO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4% hempseed oil (HO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (0% hemp)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20% hempseed (HS)
Number of subjects: 48
Study: 20224262

Group type: EXPERIMENTAL
Intervention: 3 instillations of 1% silver nitrate solution
Number of subjects: 59

Group type: COMPARATOR
Intervention: 9 instillations of 1% silver nitrate solution
Number of subjects: 59
Study: 17391132

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg b.i.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1000 mg b.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both EC-MPS and MMF
Number of subjects: 18
Study: 12781883

Group type: EXPERIMENTAL
Intervention: Scintimammography with (99m)Technetium‐Sestamibi
Number of subjects: 1734
Study: 10683057

Group type: EXPERIMENTAL
Intervention: 100 mg/d of androstenedione
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 300 mg/d of androstenedione
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0 mg/d of androstenedione (control)
Number of subjects: 42
Study: 9313385

Group type: EXPERIMENTAL
Intervention: Nutrient intake and vitamin levels assessment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Changes in body mass index over time
Number of subjects: 79
Study: 8364949

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg intramuscularly every 3 to 6 hours as needed, followed by 10 mg every 4 to 6 hours)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 210

Group type: COMPARATOR
Intervention: Meperidine (100 mg intramuscularly every 3 to 6 hours as needed, followed by acetaminophen/codeine (600 mg/60 mg) orally every 4 to 6 hours)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ketorolac and Meperidine
Number of subjects: 210
Study: 2877383

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30094160

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 26984236

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 294
Study: 24434680

Group type: EXPERIMENTAL
Intervention: Penetration enhancers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DermaMembranSysteme® (DMS®)
Number of subjects: 60
Study: 22387936

Group type: EXPERIMENTAL
Intervention: 24‐h food diary (DIET‐24)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 191
Study: 20584668

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg intravenously, repeated at 24 and 48 hours post-operation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline equivalent volume)
Number of subjects: 80
Study: 19189813

Group type: EXPERIMENTAL
Intervention: Outpatient psychodynamic psychotherapy based on the Conversational Model for 2 years
Number of subjects: 2

Group type: COMPARATOR
Intervention: Outpatient psychodynamic psychotherapy based on the Conversational Model for 1 year
Number of subjects: 2
Study: 15691793

Group type: EXPERIMENTAL
Intervention: Plasmakinetic vaporesection of the prostate (PKVP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 12753536

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Dexamethasone (DXM)
Number of subjects: 142
Study: 10391601

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (17.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.6 mg) and intrathecal bupivacaine (17.5 mg)
Number of subjects: 24
Study: 8699981

Group type: EXPERIMENTAL
Intervention: Type A detergent
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Type C detergent
Number of subjects: 8
Study: 1814770

Group type: EXPERIMENTAL
Intervention: Light‐ and chemically‐cured glass‐ionomer‐based restorations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cavities both etched and bonded
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cavities restored without enamel etching or bonding system
Number of subjects: 100
Study: 6658432

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA) at 25 mg/kg body weight
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ethambutol (EMB) at 25 mg/kg body weight
Number of subjects: 113
Study: 30946709

Group type: EXPERIMENTAL
Intervention: IOP measurements during telemedicine screening
Number of subjects: 902
Study: 29944706

Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW) and daily activity tracking (DAT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Daily activity tracking (DAT)
Number of subjects: 24
Study: 26861865

Group type: EXPERIMENTAL
Intervention: CAPSYS system (intervention group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 94
Study: 24946564

Group type: EXPERIMENTAL
Intervention: Orthopedics lotion fumigation treatment (treatment group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium hyaluronate intra-articular injection (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments (treatment and control)
Number of subjects: 60
Study: 23575046

Group type: EXPERIMENTAL
Intervention: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 125 μg (2.5 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 150 μg (3 ml)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline 0.9% (0.5 ml) prior to fentanyl 150 μg (3 ml)
Number of subjects: 150
Study: 19721169

Group type: EXPERIMENTAL
Intervention: Intracapsular injection of 8 ml of 2% lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: No intracapsular anesthesia (control group)
Number of subjects: 80
Study: 17961836

Group type: EXPERIMENTAL
Intervention: Normal saline bolus (group NSB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ringer's lactate bolus (group RLB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normal saline infusion (group NSI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion (group RLI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no washout fluid)
Number of subjects: 100
Study: 14504772

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 12
Study: 10683101

Group type: EXPERIMENTAL
Intervention: Energetically optimal cadence (70 +/- 4.5 rpm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Freely-chosen cadence (83 +/- 6.9 rpm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Energetically optimal cadence (86 +/- 6.2 rpm)
Number of subjects: 10
Study: 9025819

Group type: EXPERIMENTAL
Intervention: Autogenic training with true feedback (TFB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Autogenic training with false feedback (FFB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (Control group - CTL)
Number of subjects: 18
Study: 1497157

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Meperidine (75 mg)
Number of subjects: 31
Study: 6206687

Group type: EXPERIMENTAL
Intervention: Iohexol (300 mg I/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metrizamide (300 mg I/ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iohexol and Metrizamide
Number of subjects: 40
Study: 31302514

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Number of subjects: 158
Study: 27489241

Group type: EXPERIMENTAL
Intervention: Anti-NKG2D (2 mg/kg, single subcutaneous dose)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 26241597

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction therapy (n=58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Present-centered group therapy (n=58)
Number of subjects: 116
Study: 23508680

Group type: EXPERIMENTAL
Intervention: Psychosocial and/or pharmacotherapy (sertraline)
Number of subjects: 166
Study: 21644308

Group type: EXPERIMENTAL
Intervention: Heat-sensitive point moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gaitianli (Oyster Shell and Calcium Carbonate Chewable) tablets
Number of subjects: 60
Study: 18623168

Group type: EXPERIMENTAL
Intervention: Interobserver agreement with 6 diagnostic categories
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interobserver agreement with final diagnostic categories (microscopic colitis vs nonmicroscopic colitis)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mean intraobserver agreement with 6 diagnostic categories
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mean intraobserver agreement with final diagnostic categories (microscopic colitis vs nonmicroscopic colitis)
Number of subjects: 90
Study: 16674625

Group type: EXPERIMENTAL
Intervention: Dorges laryngoscope
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 16109591

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 29
Study: 10232502

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg, increased to 160 mg after 4 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg, increased to 100 mg after 4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8674154

Group type: EXPERIMENTAL
Intervention: Single IV dose of dolasetron (1.8 mg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Multiple-dose regimen of dolasetron (0.6 mg/kg each, total 1.8 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 55
Study: 1855018

Group type: EXPERIMENTAL
Intervention: Steroid with distension
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Steroid only
Number of subjects: 47

Group type: COMPARATOR
Intervention: Distension only
Number of subjects: 47
Study: 6411441

Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg . min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg . min) + Nitroglycerin (1.5-3.0 mg/h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (3.0-6.0 mg/h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (increased dose)
Number of subjects: 12
Study: 31640881

Group type: EXPERIMENTAL
Intervention: Poster-based intervention displaying an image of eyes and blood culture sampling guidelines
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 31541008

Group type: EXPERIMENTAL
Intervention: Two-level, variable-volume epidural blood patch (EBP)
Number of subjects: 94
Study: 29691143

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index and Glycemic Load diet (n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual eating plan (n=32)
Number of subjects: 66
Study: 26743587

Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin 75 mg, simvastatin 20 mg, lisinopril 10 mg and hydrochlorothiazide 12.5 mg)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Polypill
Number of subjects: 378
Study: 24267592

Group type: EXPERIMENTAL
Intervention: Auditory-visual matching paradigm for large numerosities (3:1 ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory-visual matching paradigm for small numerosities (2:1 ratio)
Number of subjects: 0
Study: 23080351

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 89 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 155 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine HCl 50 mg
Number of subjects: 30
Study: 20206430

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg weekly during the second half of the cycle)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bromocriptine (5 mg daily during the second half of the cycle)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 140
Study: 18614930

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: HAART-naive patients
Number of subjects: 48
Study: 16023010

Group type: EXPERIMENTAL
Intervention: Low-energy ESWT without local anesthesia (n=45; 3 x 2000 pulses, total energy flux density per shock 0.09 mJ/mm2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-energy ESWT with local anesthesia (n=41)
Number of subjects: 86
Study: 12421062

Group type: EXPERIMENTAL
Intervention: Immediate yes-no testing after viewing 5 scenes for 173 ms/picture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing delays of 2 or 6 seconds after viewing 5 scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of 10 or 20 pictures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-alternative forced-choice recognition test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time passage and test interference
Number of subjects: 0